Alveolar nitric oxide concentration as a potential biomarker of fibrosis and active disease in pulmonary sarcoidosis: a pilot study.

IF 3.7 4区医学 Q1 BIOCHEMICAL RESEARCH METHODS Journal of breath research Pub Date : 2025-01-21 DOI:10.1088/1752-7163/adac82

Stefano Levra, Fabiana Giannoccaro, Maria Chernovsky, Vitina Carriero, Elisa Arrigo, Francesca Bertolini, Maurizio Balbi, Stefano Pizzimenti, Giuseppe Guida, Fabio Luigi Massimo Luigi Massimo Ricciardolo

{"title":"Alveolar nitric oxide concentration as a potential biomarker of fibrosis and active disease in pulmonary sarcoidosis: a pilot study.","authors":"Stefano Levra, Fabiana Giannoccaro, Maria Chernovsky, Vitina Carriero, Elisa Arrigo, Francesca Bertolini, Maurizio Balbi, Stefano Pizzimenti, Giuseppe Guida, Fabio Luigi Massimo Luigi Massimo Ricciardolo","doi":"10.1088/1752-7163/adac82","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Sarcoidosis is considered a T-helper (Th) 1 related disease, but a transition from Th1 to Th2 pathway activation has been postulated in sarcoidosis-associated pulmonary fibrosis (SAPF). Fraction of exhaled nitric oxide (FENO) is a marker of Th2 airway inflammation, but alveolar concentration of nitric oxide (CANO) can be measured to assess Th2 inflammation in the periphery of the lung. The aim of this study is to assess whether CANO can be considered a biomarker of SAPF or active pulmonary sarcoidosis. Methods: In this single-center retrospective study, we compared exhaled NO levels of patients with pulmonary sarcoidosis without fibrosis (N=11) with those obtained from patients with SAPF (N=15). Clinical data, as well as respiratory function tests, were also analyzed. Results: FENO (28.5 ± 16 ppb vs 30.9 ± 17.2 ppb, p=0.72) and CANO (4.4 ± 3.5 ppb vs 3.2 ± 1.7 ppb, p=0.73) levels did not differ significantly between patients with or without SAPF, even when dividing them according to treatment or disease activity. CANO appeared reduced in patients with active sarcoidosis (2.1 ± 0.8 ppb vs 4.1 ± 3 ppb, p<0.05).Conclusion: CANO cannot be considered a biomarker of SAPF. Its lower level in patients with active disease confirms the prevalence of Th1 inflammation in granuloma formation and suggests its potential role as a biomarker of active pulmonary sarcoidosis, but further studies with larger samples are needed to confirm this hypothesis.&#xD.</p>","PeriodicalId":15306,"journal":{"name":"Journal of breath research","volume":" ","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of breath research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1088/1752-7163/adac82","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMICAL RESEARCH METHODS","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Sarcoidosis is considered a T-helper (Th) 1 related disease, but a transition from Th1 to Th2 pathway activation has been postulated in sarcoidosis-associated pulmonary fibrosis (SAPF). Fraction of exhaled nitric oxide (FENO) is a marker of Th2 airway inflammation, but alveolar concentration of nitric oxide (CANO) can be measured to assess Th2 inflammation in the periphery of the lung. The aim of this study is to assess whether CANO can be considered a biomarker of SAPF or active pulmonary sarcoidosis. Methods: In this single-center retrospective study, we compared exhaled NO levels of patients with pulmonary sarcoidosis without fibrosis (N=11) with those obtained from patients with SAPF (N=15). Clinical data, as well as respiratory function tests, were also analyzed. Results: FENO (28.5 ± 16 ppb vs 30.9 ± 17.2 ppb, p=0.72) and CANO (4.4 ± 3.5 ppb vs 3.2 ± 1.7 ppb, p=0.73) levels did not differ significantly between patients with or without SAPF, even when dividing them according to treatment or disease activity. CANO appeared reduced in patients with active sarcoidosis (2.1 ± 0.8 ppb vs 4.1 ± 3 ppb, p<0.05). Conclusion: CANO cannot be considered a biomarker of SAPF. Its lower level in patients with active disease confirms the prevalence of Th1 inflammation in granuloma formation and suggests its potential role as a biomarker of active pulmonary sarcoidosis, but further studies with larger samples are needed to confirm this hypothesis. .

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

肺泡一氧化氮浓度作为肺结节病纤维化和活动性疾病的潜在生物标志物：一项初步研究

结节病被认为是一种t -辅助性（Th） 1相关疾病，但在结节病相关肺纤维化（SAPF）中，从Th1到Th2途径激活的转变已被假设。呼出一氧化氮分数（FENO）是Th2气道炎症的标志，但肺泡一氧化氮浓度（CANO）可以通过测量来评估肺周围的Th2炎症。本研究的目的是评估CANO是否可以被认为是SAPF或活动性肺结节病的生物标志物。方法：在这项单中心回顾性研究中，我们比较了无纤维化肺结节病患者（N=11）和SAPF患者（N=15）的呼出NO水平。临床资料和呼吸功能测试也进行了分析。结果：FENO（28.5±16 ppb vs 30.9±17.2 ppb, p=0.72）和CANO（4.4±3.5 ppb vs 3.2±1.7 ppb, p=0.73）水平在SAPF患者和非SAPF患者之间没有显著差异，即使根据治疗或疾病活动进行划分。活动性结节病患者的CANO减少(2.1±0.8 ppb vs 4.1±3 ppb, p

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of breath research BIOCHEMICAL RESEARCH METHODS-RESPIRATORY SYSTEM

CiteScore

7.60

自引率

21.10%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Breath Research is dedicated to all aspects of scientific breath research. The traditional focus is on analysis of volatile compounds and aerosols in exhaled breath for the investigation of exogenous exposures, metabolism, toxicology, health status and the diagnosis of disease and breath odours. The journal also welcomes other breath-related topics. Typical areas of interest include: Big laboratory instrumentation: describing new state-of-the-art analytical instrumentation capable of performing high-resolution discovery and targeted breath research; exploiting complex technologies drawn from other areas of biochemistry and genetics for breath research. Engineering solutions: developing new breath sampling technologies for condensate and aerosols, for chemical and optical sensors, for extraction and sample preparation methods, for automation and standardization, and for multiplex analyses to preserve the breath matrix and facilitating analytical throughput. Measure exhaled constituents (e.g. CO2, acetone, isoprene) as markers of human presence or mitigate such contaminants in enclosed environments. Human and animal in vivo studies: decoding the ''breath exposome'', implementing exposure and intervention studies, performing cross-sectional and case-control research, assaying immune and inflammatory response, and testing mammalian host response to infections and exogenous exposures to develop information directly applicable to systems biology. Studying inhalation toxicology; inhaled breath as a source of internal dose; resultant blood, breath and urinary biomarkers linked to inhalation pathway. Cellular and molecular level in vitro studies. Clinical, pharmacological and forensic applications. Mathematical, statistical and graphical data interpretation.